Active, not recruitingPHASE1, PHASE2NCT05864144
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Studying Acquired cystic disease-associated renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sensei Biotherapeutics, Inc.
- Principal Investigator
- Ron Weitzman, MDSensei Biotherapeutics, Inc.
- Intervention
- SNS-101 (anti-VISTA)(drug)
- Enrollment
- 98 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2027
Study locations (10)
- UCLA Hematology/Oncology, Los Angeles, California, United States
- University of Colorado Cancer Center - Anschutz Medical, Aurora, Colorado, United States
- Norton Healthcare, Louisville, Kentucky, United States
- Henry Ford Cancer, Detroit, Michigan, United States
- Icahn School of Medicine at Mt. Sinai, New York, New York, United States
- University of Pennsylvania, Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States
- Sanford Cancer Center, Sioux Falls, South Dakota, United States
- NEXT Oncology Dallas, Irving, Texas, United States
- South Texas Accelerated Research Therapeutics (START) San Antonio, San Antonio, Texas, United States
- START Mountain Region, West Valley City, Utah, United States
Collaborators
Regeneron Pharmaceuticals
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05864144 on ClinicalTrials.govOther trials for Acquired cystic disease-associated renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06882486Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic TherapyInstitut Paoli-Calmettes
- RECRUITINGPHASE1NCT07517198Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- RECRUITINGNANCT06907095Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk IndividualsGustave Roussy, Cancer Campus, Grand Paris
- RECRUITINGNANCT07461090Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost AnalysisMenoufia University
- RECRUITINGPHASE1NCT07195682A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)Bristol-Myers Squibb
- RECRUITINGPHASE1NCT07006688A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal ImpairmentServier Bio-Innovation LLC
- RECRUITINGPHASE1, PHASE2NCT07219576Retifanlimab and Ruxolitinib In Solid MalignanciesUniversity of California, San Diego
- RECRUITINGPHASE1, PHASE2NCT07239596Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell CarcinomSuzhou Suncadia Biopharmaceuticals Co., Ltd.
See all trials for Acquired cystic disease-associated renal cell carcinoma →